Brief: Asit Biotech discloses comments from the PEI on BTT009

European Medical Solutions SA

19/06/2017 06:00

June 19 (Reuters) - ASIT BIOTECH SA  ASIT.BR  
    * REPORTS PAUL-EHRLICH-INSTITUT AND PUBLISHES DETAILED 
RESULTS CLINICAL FASE III STUDY WITH GP-ASIT+ 
    * PEI AGREED THAT CPT1 REACTIVITY AT BASELINE MAY BE USED TO 
CHARACTERIZE AND IDENTIFY THE MOST APPROPRIATE PATIENTS IN A 
FUTURE PHASE III STUDY 
    * PEI GRANTED A SCIENTIFIC ADVICE SESSION TO ASIT BIOTECH TO 
REVIEW THE RESULTS OF BTT009 AND AGREE ON FURTHER CLINICAL AND 
REGULATORY DEVELOPMENTS 
 
Source text for Eikon:  ID:nBw2C3PSHa  
Further company coverage:  ASIT.BR  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))